Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: The fools

MannKind mentioned in article on Ariad...

Company

Drugs in Development Pipeline

Average Analyst Share-Price Target

TTM R&D Spending

Ariad 4 $19.13 $89 million
Vivus 1 $30.18 $26 million
MannKind (Nasdaq: MNKD ) 4 $5.20 $93 million
Human Genome Sciences (Nasdaq: HGSI ) 7 $13.64 $151 million

Sources: Yahoo! Finance, Morningstar, and S&P Capital IQ.

Each company has its blockbuster in waiting. Ariad has ponatinib; Vivus has its anti-obesity treatment Qnexa, which already received a glowing 20-2 recommendation for approval from an FDA advisory committee; MannKind is working on inhaled-insulin treatment Afrezza; and Human Genome Sciences has lupus treatment Benlysta, which seems to be so appealing that it's attracted a buyout offer from partner GlaxoSmithKline. Each of these drugs should reach approval (or rejection) stage within a year at the most, so it may not take too long for investors to find out just how valuable they really are.

http://www.fool.com/investing/high-growth/2012/06/19/how-high-can-ariad-fly.aspx

Share
New Message
Please login to post a reply